Zobrazeno 1 - 10
of 215
pro vyhledávání: '"P. Zumpe"'
Publikováno v:
Frontiers in Education, Vol 9 (2024)
IntroductionTwo rising innovations in educational leadership development—using an equity lens and facilitating continuous improvement (CI)—depend upon leaders developing conducive mindsets for the work. However, little research has examined how e
Externí odkaz:
https://doaj.org/article/9a80536ca1ae4912a4bcd2d0b3acac5a
Autor:
Hannes Forkel, Piotr Grabarczyk, Maren Depke, Sascha Troschke-Meurer, Stefan Simm, Elke Hammer, Stephan Michalik, Christian Hentschker, Björn Corleis, Lucie Loyal, Maxi Zumpe, Nikolai Siebert, Anca Dorhoi, Andreas Thiel, Holger Lode, Uwe Völker, Christian A. Schmidt
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
ABSTRACTBCL11B, an essential transcription factor for thymopoiesis, regulates also vital processes in post-thymic lymphocytes. Increased expression of BCL11B was recently correlated with the maturation of NK cells, whereas reduced BCL11B levels were
Externí odkaz:
https://doaj.org/article/38c9a1f16c6741208dbf26b7a38a18f3
Autor:
Peter Ward, Peter Dahlberg, Ole Lagatie, Joel Larsson, August Tynong, Johnny Vlaminck, Matthias Zumpe, Shaali Ame, Mio Ayana, Virak Khieu, Zeleke Mekonnen, Maurice Odiere, Tsegaye Yohannes, Sofie Van Hoecke, Bruno Levecke, Lieven J Stuyver
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 6, p e0010500 (2022)
BackgroundWith the World Health Organization's (WHO) publication of the 2021-2030 neglected tropical diseases (NTDs) roadmap, the current gap in global diagnostics became painfully apparent. Improving existing diagnostic standards with state-of-the-a
Externí odkaz:
https://doaj.org/article/db16e315d1c94f219d606ee5a388babb
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 721 (2023)
Oral mucositis is the most common and severe non-hematological complication associated with cancer radiotherapy, chemotherapy, or their combination. Treatment of oral mucositis focuses on pain management and the use of natural anti-inflammatory, some
Externí odkaz:
https://doaj.org/article/51cf3d2ec03548a6849a6412d9537733
Autor:
Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desireé Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang, Patrick Schlegel
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The
Externí odkaz:
https://doaj.org/article/3db6c45432c649c5ab96cdd2344832c5
Publikováno v:
Procedia CIRP; 2024, Vol. 122, p789-794, 6p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert, Holger N. Lode
Publikováno v:
Frontiers in Pediatrics, Vol 8 (2020)
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninet
Externí odkaz:
https://doaj.org/article/d64eecd9b1d8462d88e41db19379f01a
Autor:
Nikolai Siebert, Maxi Zumpe, Leon von Lojewski, Sascha Troschke-Meurer, Madlen Marx, Holger N. Lode
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Neuroblastoma (NB) still remains a major challenge in pediatric oncology. We recently showed CD11b+-dependent upregulation of the PD-1/PD-L1 checkpoint on NB cells treated with the chimeric anti-GD2 antibody (Ab) ch14.18/CHO. Here, we report effects
Externí odkaz:
https://doaj.org/article/c4972936abb24748a9d0e6ea4e1fdc35
Autor:
Sascha Troschke-Meurer, Nikolai Siebert, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Oliver Mutschlechner, Hans Loibner, Ruth Ladenstein, Holger N. Lode
Publikováno v:
OncoImmunology, Vol 8, Iss 12 (2019)
Immunotherapy with the anti-GD2 antibody (Ab) ch14.18/CHO in combination with interleukin 2 (IL-2) has improved survival of high-risk neuroblastoma (NB) patients. Here, we report immunotherapy-related effects on circulating NK cells, regulatory T cel
Externí odkaz:
https://doaj.org/article/1add2821f0c7408d98e60669870206e0